

**AMENDMENTS TO THE CLAIMS
PURSUANT TO REVISED 37 CFR § 1.121**

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

Claims 1 – 17 (Cancelled).

18. (Previously Presented) A method of treating migraines, comprising:
a) providing:
i) a patient having one or more symptoms of a migraine and,
ii) a formulation comprising dihydroergotamine and a steroid;
b) administering said formulation to said patient sublingually under conditions such that said one or more symptoms of said migraine are reduced.
19. (Previously Presented) The method of Claim 18, wherein said dihydroergotamine is a pharmaceutically accepted salt.
20. (Previously Presented) The method of Claim 18, wherein said dihydroergotamine is a pharmaceutically accepted base.
21. (Previously Presented) The method of Claim 18, wherein said steroid is a glucocorticoid.
22. (Previously Presented) The method of Claim 21, wherein said glucocorticoid is selected from the group consisting of cortisol, cortisone, prednisolone and, dexamethasone.
21. (Previously Presented) The method of Claim 18, wherein said sublingual administration is via a tablet or compressed powder.
22. (Previously Presented) The method of Claim 21, wherein said tablet is fast dissolving.

23. (Previously Presented) A method of treating migraine comprising: the application of a tablet to the sublingual mucosa of a patient wherein said consists of two active ingredients and one or more inactive ingredients, wherein said active ingredients are: i) dihydroergotamine and, ii) a steroid and wherein at least one of said one or more inactive ingredients is selected from the group consisting of: i) nondirect compression filler and, ii) a lubricant.